Edwards Lifesciences Corp — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Edwards Lifesciences reported Q2 2026 net sales of $1.741 billion (13.6% reported, 12.5% constant currency growth vs. Q2 2025: $1.532B). TAVR sales grew 10.5% cc to $1.258B; TMTT grew 44.8% cc to $198.6M; Surgical grew 5.0% cc to $284.1M. Adjusted EPS: $0.78 (vs. $0.67 prior year). Company raised full-year 2026 sales guidance to 10-11% cc growth (from 9-11%), TAVR to 8-9% (from 7-9%), and TMTT to $760-780M (from $740-780M). However, a $188.2M California R&D tax credit valuation allowance (enacted June 29, 2026) reduced net income and effective tax rate to 53.6% GAAP for Q2; adjusted tax rate 18.6%. Company reaffirmed adjusted EPS guidance of $2.95-3.05 for full year despite tax headwind.
Why this rating
Strong topline beat and guidance raise offset by one-time $188M tax charge. Structural heart growth solid but not transformational relative to $45.9B market cap. Tax law change is material short-term but non-recurring.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.